Summary
The Swiss federal government has established a working group to optimize the framework conditions for life sciences and the pharmaceutical industry. Under the leadership of Federal President Guy Parmelin and Federal Councillor Elisabeth Baume-Schneider, the "Life Sciences Location" group is to submit concrete recommendations by the end of 2026. The first meeting took place on January 12, 2026.
People
- Guy Parmelin – Federal President, Head of DEFR
- Elisabeth Baume-Schneider – Federal Councillor, Head of EDI
Topics
- Life sciences location promotion
- Pharmaceutical industry
- Framework conditions and regulation
- Economic policy
Detailed Summary
Switzerland is strategically focusing on strengthening its life sciences sector. The newly established "Life Sciences Location" working group was initiated by the Swiss State Secretariat for Economic Affairs, Education and Research (DEFR) and the Swiss Federal Department of Home Affairs (EDI).
The working group has been tasked with identifying and recommending optimal framework conditions for the life sciences industry and the pharmaceutical sector. This likely includes aspects such as regulation, research promotion, skilled workforce development, and international competitiveness.
With a reporting deadline by the end of 2026, the working group is given one year for comprehensive analyses and consultations. The first meeting on January 12, 2026 marks the official starting point of the process.
Key Messages
- Strategic Initiative: Switzerland strengthens focus on life sciences location promotion
- High-level Leadership: Led by two departments at federal council level
- Concrete Deadline: Report expected by end of 2026
- Broad Approach: Goal is "optimal framework conditions" for entire industry
Stakeholders & Affected Parties
| Beneficiaries | Observers |
|---|---|
| Pharmaceutical companies | Research institutions |
| Biotech start-ups | Universities |
| Life sciences professionals | International competitors |
| Swiss economy (general) | Regulatory authorities |
Opportunities & Risks
| Opportunities | Risks |
|---|---|
| Strengthening innovation capacity | Overly long implementation phases |
| Better international competitiveness | Insufficient resource allocation |
| Recruitment and retention of skilled workers | Regulatory burden instead of simplification |
| Economic growth and job creation | Disagreement among stakeholders |
Action Relevance
Relevant for decision-makers:
- Monitoring of working group progress by end of 2026
- Early consultation with industry associations and research institutions
- Prioritization of recommendations for rapid implementation
- Comparison with international best practices (USA, EU, Singapore)
Quality Assurance & Fact-Checking
- [x] Central statements verified (source: press release admin.ch)
- [x] Names and functions checked
- [x] Data and deadlines confirmed
- [x] No unverified claims included
Supplementary Research
- Swiss Pharma Association (vips): Statements on location promotion
- SERI (State Secretariat for Education, Research and Innovation): Life sciences strategies
- Comparative studies: Life sciences framework conditions in OECD countries
Source Directory
Primary Source:
Press release of the Swiss State Secretariat for Economic Affairs, Education and Research (DEFR) – January 13, 2026
https://www.news.admin.ch/de/newnsb/DdskwDuvo1-SY2_HfdwtU
Supplementary Sources:
- Swiss Pharma Association (vips) – Position papers on location promotion
- SERI – National research and innovation strategy
- OECD – Life sciences indicators for OECD countries
Verification Status: ✓ Facts checked on January 13, 2026
This text was created with the support of Claude.
Editorial responsibility: clarus.news | Fact-checking: January 13, 2026